Evaluating enrollment and representation in COVID-19 and HIV vaccine clinical trials

被引:0
作者
Lezo Ramirez, Daisy [1 ]
Koleske, Emily [1 ]
Ometoruwa, Omolola [1 ]
Park Chang, Jun Bai [1 ]
Kanwal, Urwah [1 ]
Morreale, Nicholas [1 ]
Avila Paz, Andres Alberto [1 ]
Tong, Alexandra [1 ]
Baden, Lindsey R. [1 ,2 ]
Sherman, Amy C. [1 ,2 ]
Walsh, Stephen R. [1 ,2 ]
机构
[1] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02130 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
关键词
clinical trial enrollment; diversity; representation; vaccine; HIV; SARS-CoV-2; HEALTH; MINORITIES; GENDER; SEX;
D O I
10.3389/fpubh.2024.1411970
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Vaccine clinical trials should strive to recruit a racially, socioeconomically, and ethnically diverse range of participants to ensure appropriate representation that matches population characteristics. Yet, full inclusion in research is often limited.Methods A single-center retrospective study was conducted of adults enrolled at Brigham and Women's Hospital (Boston, MA) between July 2020 and December 2021. Demographic characteristics, including age, race, ethnicity, ZIP code, and sex assigned at birth, were analyzed from both HIV and COVID-19 vaccine trials during the study period, acknowledging the limitations to representation under these parameters. We compared the educational attainment of vaccine trial participants to residents of the Massachusetts metropolitan area, geocoded participants' addresses to their census block group, and linked them to reported median household income levels from publicly available data for 2020. Frequency and quartile analyses were carried out, and spatial analyses were performed using ArcGIS Online web-based mapping software (Esri).Results A total of 1030 participants from four COVID-19 vaccine trials (n = 916 participants) and six HIV vaccine trials (n = 114 participants) were included in the analysis. The median age was 49 years (IQR 33-63) and 28 years (IQR 24-34) for the COVID-19 and HIV vaccine trials, respectively. Participants identifying as White were the majority group represented for both the COVID-19 (n = 598, 65.3%) and HIV vaccine trials (n = 83, 72.8%). Fewer than 25% of participants identified as Hispanic or Latin. Based on ZIP code of residence, the median household income for COVID-19 vaccine clinical trial participants (n = 846) was 102,088 USD (IQR = 81,442-126,094). For HIV vaccine clinical trial participants (n = 109), the median household income was 101,266 USD (IQR 75,052-108,832).Conclusion We described the characteristics of participants enrolled for HIV and COVID-19 vaccine trials at a single center and found similitude in geographical distribution, median incomes, and proportion of underrepresented individuals between the two types of vaccine candidate trials. Further outreach efforts are needed to ensure the inclusion of individuals from lower educational and socioeconomic brackets. In addition, continued and sustained efforts are necessary to ensure inclusion of individuals from diverse racial and ethnic backgrounds.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Combination therapies for COVID-19: An overview of the clinical trials landscape
    Akinbolade, Sola
    Coughlan, Diarmuid
    Fairbairn, Ross
    McConkey, Glenn
    Powell, Helen
    Ogunbayo, Dapo
    Craig, Dawn
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (04) : 1590 - 1597
  • [42] The COVID-19 Vaccine Landscape
    Koch, Till
    Fathi, Anahita
    Addo, Marylyn M.
    CORONAVIRUS DISEASE - COVID-19, 2021, 1318 : 549 - 573
  • [43] Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives
    Kotta, Sabna
    Aldawsari, Hibah Mubarak
    Badr-Eldin, Shaimaa M.
    Alhakamy, Nabil Abdulhafiz
    Md, Shadab
    Nair, Anroop B.
    Deb, Pran Kishore
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2020, 7
  • [44] Understanding COVID-19 Vaccine Confidence in People Living with HIV: A pan-Canadian Survey
    Costiniuk, Cecilia T.
    Singer, Joel
    Needham, Judy
    Yang, Yanbo
    Qian, Hong
    Chambers, Catharine
    Burchell, Ann N.
    Samji, Hasina
    Colmegna, Ines
    del Canto, Sugandhi
    Godin, Guy-Henri
    Habanyama, Muluba
    Hui, Christian
    Kroch, Abigail
    Mandarino, Enrico
    Margolese, Shari
    Martin, Carrie
    Owino, Maureen
    Mohammadi, Tima
    Zhang, Wei
    Pelaez, Sandra
    Kovacs, Colin
    Benko, Erika
    Vulesevic, Branka
    Cooper, Curtis L.
    Anis, Aslam H.
    AIDS AND BEHAVIOR, 2023, 27 (08) : 2669 - 2680
  • [45] COVID-19 vaccine safety
    Kostoff, Ronald N.
    Briggs, Michael B.
    Porter, Alan L.
    Spandidos, Demetrios A.
    Tsatsakis, Aristidis
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2020, 46 (05) : 1599 - 1602
  • [47] India and the COVID-19 vaccine
    Satish, Karthyayani Priya
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (01)
  • [48] Clinical application of COVID-19 vaccine in liver transplant recipients
    Liu, Feng-Chao
    Xie, Man
    Rao, Wei
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2024, 23 (04) : 339 - 343
  • [49] Factors associated with the intention to participate in COVID-19 vaccine clinical trials: A cross-sectional study in Peru
    De-los-Rios-Pinto, Abraham
    Fernandez-Guzman, Daniel
    Soriano-Moreno, David R.
    Sangster-Carrasco, Lucero
    Morocho-Alburqueque, Noelia
    Pinedo-Soria, Antony
    Murrieta-Ruiz, Valentina
    Diaz-Corrales, Angelica
    Alave, Jorge
    Nieto-Gutierrez, Wendy
    Gonzales-Zamora, Jose
    VACCINE, 2022, 40 (26) : 3566 - 3572
  • [50] Exclusion of older adults and immunocompromised individuals in influenza, pneumococcal and COVID-19 vaccine trials before and after the COVID-19 pandemic
    Bukan, Katrine
    Pearce-Slade, Toby
    Eiberg, Mads
    Tinelli, Marco
    Yahav, Dafna
    Tuells, Jose
    Epaulard, Olivier
    Holler, Jon G.
    Roed, Casper
    Soborg, Christian
    Jensen, Jens-Ulrik Staehr
    Harboe, Zitta Barrella
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 (05) : 917 - 923